Data-Driven Strategy & Investment Banking
Back Bay is the only life sciences group that integrates seasoned strategic insight with investment banking capabilities to provide comprehensive guidance to global life sciences companies and their investors. Our team has the expertise to advise clients through complex business, scientific and financial challenges.
Boutique Feel & Global Reach
Global biotech. Pharmaceutical. Medical device companies. Investors. Academic centers of technology development. Government incubators. These are the organizations that rely on Back Bay for strategic guidance and responsive client service across their commercial, R&D, corporate business development and investment banking opportunities in the US and around the world.
DNB Carnegie Back Bay Healthcare Partnership
A unique integrated strategy and corporate and investment banking solution for global and emerging life science and healthcare companies.
The DNB Carnegie Back Bay Healthcare Partnership provides essential strategic and financial support to healthcare companies.
Hosted by DNB Carnegie Back Bay, the NAHC unites large and mid-cap public and private IPO-ready US and Nordic life science companies with US institutional healthcare investors. Participating companies showcase leading products that offer substantial advancements in patient care, making them highly appealing investment opportunities.
Recent activity across healthcare equity markets, M&A and venture financing across the US and EU.
This executive summary from the Investment Banking Division of DNB Carnegie Back Bay focuses on a macro environment overview of current US economic markets, policy and regulatory updates in light of the current administration’s full-spectrum overhaul of US healthcare policies and the life science ecosystems and healthcare market activity as it relates to healthcare dealmaking in the US and Europe.
Despite the size of the ever-growing inflammatory bowel disease (IBD) drug market and its diversity of modalities from JAK inhibitors to IL-23s, unmet needs and treatment gaps remain.
The latest in our series of healthcare analyst reports focuses on the mitogen-activated protein kinase (MAPK) pathway, one of the most commonly perturbed signaling pathways in human cancer.
Life Sciences Development and Commercialization Financing
We guide biotech, pharmaceutical and medical technology companies and their investors on the development, commercialization, growth and maintenance of market share, by providing the insight needed to drive growth and create value. Together we can capitalize on opportunity, increase shareholder value and improve patient care.